Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18
November 14, 2019Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here.
In this Phase 2a trial Epeleuton significantly decreased triglycerides, HbA1C, fasting glucose and multiple inflammatory markers. These data suggest Epeleuton has potential for the treatment of hypertriglyceridemia, type 2 diabetes, non-alcoholic fatty liver disease and the reduction of cardiovascular risk by simultaneously targeting high triglycerides, HbA1c and systemic inflammation.
The 240 patient Phase 2b ‘TRIAGE’ trial in patients with type 2 diabetes and hypertriglyceridemia to confirm these significant findings started in August 2020.